Join us at the upcoming World Drug Repositioning Congress, 4 – 5 December 2012, 20 F Street NW Conference Center, Washington, DC, US Biovista’s Aris Persidis is presenting a talk titled Very large scale systematic drug repositioning as a business and technology driver Topics covered include: Big data technologies enabling the deployment of systemic drug … Read More
Author: Christos Andronis
Partnering for Cures meeting
Join us at the upcoming Partnering for Cures meeting, November 28-30, 2012 in NY City. Biovista will be co-presenting with the CFIDS Association of America its repositioning work on Chronic Fatigue Syndrome within the event’s prestigious Innovator Presentations session. The session focuses on organizations “engaged in innovative, cross-sector collaborations aimed at reducing the time … Read More
The Path of Least Resistance: Repositioned Drugs Surpass New Brands
Article by PharmExec’s Clark Herman on the 505(b)(2) pathway for drug approval … Aris Persidis, president and co-founder of Biovista, a company focused on the 505(b)(2), adds, “In addition, the first to file patent regulations that will take effect in the US next year are making companies realize that they may be susceptible to competitors … Read More
Train: CFIDS INNOVATOR SPOTLIGHT
Q&A with K. Kimberly McCleary President & CEO The CFIDS Association of America A 2011 article in The Scientist alerted Suzanne to companies applying informatics to drug repurposing. One of them, Biovista, applied to our 2011 funding opportunity and its proposal to identify non-obvious drug therapies for CFS scored well for scientific and strategic merit. … Read More
Research 1st: Repurposing Old Drugs for CFS
Biovista and its VP for Drug Discovery, Dr. Spyros Deftereos, MD, are featured in an online article in relation to CFIDS Association’s Research Institute Without Walls (RIWW) … The process of drug repurposing, also called “drug repositioning,” can slash the time and cost to bring new therapies to the patients who need them most, says … Read More